in fonal Application No FCI/GB2004/005080

A. CLASSIF IPC 7	CO7F9/00	MATTER A61K31/28	A61P5/00	A61P25/00	
According to	International Patent Class	sification (IPC) or to bot	n national classification	n and IPC	
B. FIELDS	SEARCHED				
Minimum doo IPC 7	cumentation searched (d CO7F A61K	assification system folio A61P	wed by classification	symbols)	
Documentati	on searched other than m	inimum documentation	to the extent that suc	h documents are included in the fields	searched
Electronic da	ta base consulted during	the international searc	h (name of data base	and, where practical, search terms use	ed)
	ternal, CHEM <i>F</i>				
C. DOCUME	ENTS CONSIDERED TO				
Category °	Citation of document, w	ith Indication, where ap	propriate, of the relev	ant passages	Relevant to claim No.
P,X	"Bisperoxov PTEN inhib FEBS LETTE	RS , 566(1-3) SN: 0014-5793	oounds are p), 35-38 COD	DEN:	1-12
x	peroxovana glucose tr and contra DIABETES .	RAINE A. ET / dium compound ansport as po ctions combio 52(8), 1918- -1797, 2003, document	d stimulates owerfully as ned" -1925 CODEN: XP002318470	s insulin : DIAEAZ;)	1-8,12
			-,	/	
X Fur	ther documents are listed	In the continuation of b	ox C.	X Patent family members are liste	
"A" docum	ategories of cited docume tent defining the general s dered to be of particular r	state of the art which is elevance	not	T* later document published after the or priority date and not in conflict v cited to understand the principle or invention	vith the application but refer theory underlying the
filing "L" docum which	ent which may throw dou i is cited to establish the p	bts on priority claim(s) on priority claim(s) on priority claim(s) on the canoth	or	 X' document of particular relevance; the cannot be considered novel or can involve an inventive step when the Y' document of particular relevance; the 	inot be considered to document is taken alone ne claimed invention
O docum	on or other special reason nent referring to an oral di means nent published prior to the	sclosure, use, exhibitio	but	cannot be considered to involve an document is combined with one or ments, such combination being ob in the art.	rmore other such cocu- wious to a person skilled
later	than the priority date chair	ned		'&' document member of the same pat Date of mailing of the international	
	e actual completion of the L March 2005	ulemalional search		10/03/2005	
Name and	mailing address of the IS	Α		Authorized officer	
	NL - 2280 HV Rijs	2040, Tx. 31 651 epo ni		Rinkel, L	

Application No /GB2004/005080

		/GB2004/005080	
	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT	Indiana and the	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Х	BAND, CHRISTIAN J. ET AL: "Early signaling events triggered by peroxovanadium 'bpV(phen)! are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase (s) by bpV(phen)" MOLECULAR ENDOCRINOLOGY, 11(13), 1899-1910 CODEN: MOENEN; ISSN: 0888-8809, 1997, XP002318471 the whole document	1-8,12	
X	BAND, CHRISTIAN J. ET AL: "Phosphatidylinositol 3'-kinase and p70s6k are required for insulin but not bisperoxovanadium 1,10-phenanthroline (bpV(phen)) inhibition of insulin-like growth factor binding protein gene expression. Evidence for MEK-independent activation of mitogen-activated protein kinase by bpV(phen)" JOURNAL OF BIOLOGICAL CHEMISTRY, 272(1), 138-145 CODEN: JBCHA3; ISSN: 0021-9258, 1997, XP002318472 cited in the application the whole document	1-8,12	
X	US 2003/055106 A1 (FAURE, ROBERT ET AL) 20 March 2003 (2003-03-20) the whole document	1-8,12	
X	BARAT, CORINNE ET AL: "Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2 Gene" JOURNAL OF BIOLOGICAL CHEMISTRY, 278(9), 6992-7000 CODEN: JBCHA3; ISSN: 0021-9258, 2003, XP002318473 the whole document	1-8,12	
X	WO 00/57860 A2 (CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER, CAN.) 5 October 2000 (2000-10-05) the whole document	1-8,12	
Ρ,Χ	WO 2004/018655 A2 (NEURONOVA AB, SWED.) 4 March 2004 (2004-03-04) the whole document	1-8,12	
	-/		
	·		
		Ì	

Application No PC1/GB2004/005080

0.400=11=	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	FC17 BB20047 003000
C.(Continua Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Calegory	Carlott of Goodings, same	
X	SASAGAWA, TAKAHIRO ET AL: "Bis(6-ethylpicolinato)oxovanadium(IV) complex with normoglycemic activity in KK-Ay mice" JOURNAL OF INORGANIC BIOCHEMISTRY, 88(1), 108-112 CODEN: JIBIDJ; ISSN: 0162-0134, 2002, XP002318474 the whole document	10,12
X.	KOZLOV, ALEXANDER ET AL: "Zeolite-encapsulated vanadium picolinate peroxo complexes active for catalytic hydrocarbon oxidations" JOURNAL OF MOLECULAR CATALYSIS A: CHEMICAL, 137(1-3), 223-237 CODEN: JMCCF2; ISSN: 1381-1169, 1999, XP002318475 the whole document	10
Ρ,Χ	GB 2 396 106 A (JOHNSON & JOHNSON MEDICAL LIMITED, UK) 16 June 2004 (2004-06-16) the whole document	1-8,12

Application No PC1/GB2004/005080

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 2003055106	A1	20-03-2003	CA	2280249	A1	12-02-2001
			AU	6550900	Α	13-03-2001
			BR	0013147	Α	23-07-2002
			WO	0112180	A2	22-02-2001
			CA	2314915	A1	12-02-2001
			EP	1202728	A2	08-05-2002
			JΡ	2003506487	T	18-02-2003
			MΧ	PA02001481	Α	21-07-2003
			NZ	517159	Α	30-04-2004
WO 0057860	A2	05-10-2000	AU	3412600	Α	16-10-2000
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			CA	2365122	A1	05-10-2000
			EP	1165098	A2	02-01-2002
WO 2004018655	A2	04-03-2004	NONE			
GB 2396106	Α	16-06-2004	WO	2004052412	A1	24-06-2004